OncoMatch/Clinical Trials/NCT06632262
A Phase 2 Clinical Study of ABSK061 and ABSK043
Is NCT06632262 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including ABSK061 + ABSK043 and ABSK061+ABSK043 in combination with CAPOX for her2-gastric/gastroesophageal junction cancer.
Treatment: ABSK061 + ABSK043 · ABSK061+ABSK043 in combination with CAPOX — The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Urothelial Carcinoma
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Required: FGFR2 activating mutation
FGFR2/3 activating mutations
Required: FGFR3 activating mutation
FGFR2/3 activating mutations
Required: FGFR2 fusion/rearrangement
FGFR2/3 fusions/rearrangements
Required: FGFR3 fusion/rearrangement
FGFR2/3 fusions/rearrangements
Required: FGFR2 amplification
FGFR2 amplification
Required: FGFR2 overexpression
FGFR2 overexpression
Required: FGFR3 overexpression
FGFR3 overexpression
Disease stage
Metastatic disease required
Performance status
WHO 0–1
Prior therapy
Cannot have received: FGFR pathway inhibitor
Previous treatment with an FGFR pathway inhibitor or a multi-kinase inhibitor designed to inhibit FGFR
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06632262 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FGFR pathway inhibitor disqualifies patients from enrollment.
Does this trial require FGFR2?
Yes, FGFR2 activating mutation is a required biomarker for enrollment.
Does this trial require FGFR3?
Yes, FGFR3 activating mutation is a required biomarker for enrollment.
Does this trial require FGFR2?
Yes, FGFR2 fusion/rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify